Pharm-Olam
Pharm-Olam is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized two-arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate to severe chronic peripheral neuropathic pain due to postherpetic neuralgia or peripheral nerve injury.
Sponsor Merz Therapeutics GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- Participants were recruited at 26 sites in Bulgaria, France, Germany, Hungary, Poland, and Spain.
- A protocol amendment specified adjustment of primary and secondary efficacy analyses for painful skin surface area as a potential confounder or modifier because it was proportional to planned injection points.
- A subsequent protocol amendment reduced the maximum NT 201 dose to 300 U, added pulmonary function tests, adapted the visit schedule, and simplified eCOA data collection.
These findings describe the trial, not the service provider’s performance or responsibility.
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Pharm-Olam?
The 2026-10-09 snapshot links Pharm-Olam to 2 distinct CTIS trials. Recorded services include Clinical monitoring, Medical expertise, Project management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pharm-Olam?
The most frequently recorded therapeutic areas are Neurology, Pain Medicine. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pharm-Olam conducted?
The linked trials record locations in 7 countries, including Germany, Hungary, Bulgaria, Spain, France. These are trial locations, not confirmed office locations or countries where Pharm-Olam delivered services.
What can this page tell me about Pharm-Olam's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Pharm-Olam. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Pharm-Olam International (UK) Limited
- Pharm-Olam International Deutschland GmbH